Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03734016 · ClinicalTrials.gov registry record · Phase 3

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeiGene.

Completed
Registry status
Phase 3
Development phase
652
Enrollment target
20
Study locations

NCT03734016 is a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that has completed, run by BeiGene. The registered enrollment target is 652 participants, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (266% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03734016, a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, has completed, sponsored by BeiGene.

COMPLETED
Registry status
Phase 3
Development phase
652 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions

  • DRUG Zanubrutinib
  • DRUG Ibrutinib

Study Locations (20)

Florida

  • Scri Florida Cancer Specialists South - Fort Myers
  • Scri Florida Cancer Specialists North - St. Petersburg

New Jersey

  • Atlantic Health System - Morristown
  • Morristown Medical Center - Morristown

New York

  • Columbia University Medical Center - New York
  • Clinical Research Alliance, Inc - Westbury

Oregon

  • Oregon Health and Science University - Portland
  • Willamette Valley Cancer Center - Springfield

Arkansas

  • Carti Cancer Center - Little Rock

California

  • David Geffen School of Medicine At UCLA - Los Angeles

Colorado

  • Rocky Mountain Cancer Centers Boulder - Boulder

Georgia

  • Augusta University - Augusta

Trial Details

FieldValue
Enrollment Target 652 participants
Start Date 2018-11-01
Est. Completion 2024-02-28
Phase Phase 3

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03734016

The ClinicalTrials.gov registry entry for NCT03734016 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 652 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (266% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.

NCT03734016 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT03734016 about?

NCT03734016 is a clinical study titled "A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia". This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

What is the current status of trial NCT03734016?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 652 participants. The study started on 2018-11-01. Estimated completion is 2024-02-28.

What conditions does trial NCT03734016 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT03734016?

The interventions under investigation include: Zanubrutinib (DRUG), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT03734016?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03734016 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Small Lymphocytic Lymphoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.